From Mystery to Measurable: The Quest for Clarity in Autoimmune Disease

When your immune system turns against your body, the symptoms don’t always show up clearly—or all at once. For millions living with autoimmune diseases like Lupus, the path to diagnosis can feel like wandering in the dark: years of unexplained fatigue, unexplained rashes, joint pain, or brain fog—only to be told, "Your labs are normal."

At Tashkhīs, we believe that no one should have to wait years to be believed. And certainly, no one should have to get sicker before being diagnosed.

The Problem: Medicine Isn’t Built for Complexity

Autoimmune diseases are notoriously heterogeneous—they manifest differently in every person. Some patients have clear antibody markers. Others don’t. Some develop organ involvement early. Others don’t until years later.

This complexity means many patients:

• Get misdiagnosed (as depression, anxiety, fibromyalgia…)

• Don’t qualify for clinical trials

• Or worse—go untreated until irreversible damage occurs

Standard diagnostic tools weren’t built to capture this kind of variation.

The Opportunity: A New Lens on the Immune System

At Tashkhīs, we’re developing an entirely new approach—using multi-omics data (gene expression, protein biomarkers, cytokine levels) to read the immune system in real time.

Instead of relying solely on antibodies like ANA or dsDNA, we use a set of molecular signatures—like interferon-stimulated genes (IFI27, ISG15, MX1), SIGLEC-1, and BAFF—that appear much earlier in the disease process.

With AI, we can process and interpret thousands of immune data points from a single blood sample—delivering insights even when traditional tests say “everything’s normal.”

This Isn’t Just About Data. It’s About People.

We started Tashkhīs because we’ve seen firsthand what delayed diagnosis looks like:

• A teenager forced to quit school because no one believed her joint pain.

• A father misdiagnosed with chronic fatigue when it was early-stage lupus.

• A child developing kidney damage before the disease was even named.

Behind every biomarker is a person. Behind every delayed test result is a life on hold.

Where We’re Going Next

We're collaborating with hospitals and research partners to:

• Validate our diagnostic platform in real-world autoimmune populations

• Support atypical and seronegative patients

• Build tools that adapt to regional and ethnic variations in disease expression

Final Thought: Complexity Isn’t the Enemy. It’s the Clue.

Autoimmune diseases are complex, but that doesn’t mean they’re unknowable. With better tools, deeper data, and a commitment to equity—we can shift diagnosis from being a game of elimination to a science of detection.

If you’re a patient, clinician, or researcher ready to rethink what’s possible—join us.